Evogene Ltd. — Investor Presentation 2019

Mar 18, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2019

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 A Slide Presentation: AgPlenus Company Introduction – March 2019.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: March 18, 2019

By: /s/ Dorit Kreiner

——————————————

Dorit Kreiner Chief Financial Officer

3

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION 99.1 A Slide Presentation: AgPlenus Company Introduction – March 2019.

iagPlenus

Effective and Sustainable Crop Protection

Company introduction

Mar 2019

Safe Harbor Statement

This presentation contains "forward-looking statements, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "goal," "should," "planned," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA

Such statements are based on current expectations and assumptions, describe opinions about future events, involve certain risks and uncertainties which to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information or to publicly release the results of any revisions to any statements that may be made to reflect future events or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

All rights reserved to AgPierus Lat. O

• WagPlenus - 2 -

VISION

To design effective and sustainable crop protection products by leveraging predictive biology

Large and growing market

All rights reserved in AgPierus Links

• 4 agPlenus - 4 -

Dire need for effective and sustainable innovative products

Awareness to environment tox. effects and toxicity to beneficials	The Pesticide Cycle Loscope of
No new herbicide with new MoA (Mode of Auxin Action) launched for 30 years	VLCFA Cellulose DX8 CytOx Microtubule PS II ALB ACCase 888embly (Oxaziciomefone) Microlubula PPO DHPS PDS ceganisation GS (Cinmethylin) EPSPS PSI HPPD 1970 1950 1960 1980 1990 2000 2010 2019
	A new approach is needed for crop protection innovation

Disruptive technology to deliver novel crop protection products

AgPlenus' business strategy

Strategy - high value revenue sharing deals based on Internal pipeline of Leads and Optimized Leads

All rights resirved to AgPierus Link O

AgPlenus' business strategy - 5 year milestones plan

AgPlenus' product pipeline and collaborations

New MoA Herbicides pipeline - AG14503

In-planta results

Innovative & experienced management team

Eran Kosover CEO

Experienced technological Jeader

Evogene EVP & GM Crop Protection,
Atera Networks POC Hi-Tech, consulting

MA Economics

Ofir Hazut BD and Strategy

Vast start-up experience

MEway Pharma, DiagnosticAid Medical,

MSc Neuroscience, MBA

Boaz Inbal R&D

Extensive development background

Epix pharmaceuticals, Insilicore, Promining the rapeutics

PhD Molecular biology, biochemistry & bioinformatics

Mirit Ram Director of PM

Focused technological development

Evogene,
FMC, HP

MSc chemical engineering

Board of Directors

Ofer Haviv Chairman of the board Evogene, CEO

Adrian Percy Bayer crop science: Ag Technology Ambassador Head of Research & Development Head of Global Regulatory Affairs VP, Development North America

Robert A. Woods Marrone Bio Innovations, Chairman Gowan LLC, Director Bioenterprise capital private equity, Syngenta, President Crop Protection

Eli Assraf Galam Ltd, Director Makhteshim Agan (Adama), CFO Strauss Group, CFO

All rights resizved in AgPierus im O

• CagPlenus - 12 -

AgPlenus highlights

Company

• · Addressing the large and growing crop protection market strong need for innovation
• · Leveraging computational predictive biology to design next generation crop protection products
• · Promising pipeline Herbicidal 'Hits' and Insecticidal novel targets
• · Ongoing collaborations: BASF (Herbicides 2016 and Insecticides 2018) and ICL (2017)
• · Exclusive license for Evogene's technologies for the field of Ag-chemistry (which represent \$10M's of investments)
• · Leading management and scientific team
• · Highly experienced BoD & scientific advisory

Internal pipeline highlights

First Lead compound expected in 2 years (2021):

• · Type: new mode of action Herbicide
• · We estimate the market value of a lead compound: \$50Ms \$100Ms

All rights reserved to AgPierus Link O

CagPlenus - 13 -